Academic and Professional Qualifications:
Dr Belamy Cheung, BMed, MSc, PhD
Principal Scientist and Research Manager, Embryonal Cancer Therapy and Prevention
Children’s Cancer Institute Australia
Lowy Cancer Research Centre, University of NSW
PhD Student Supervisor and Senior Lecturer (UNSW)
Dr Belamy Cheung is internationally regarded as a childhood cancer researcher with a strong established track record. She has 66 publications with more than 2500 citations in childhood cancer research. As the Principal Scientist and Program Manager at Children's Cancer Institute Australia, she leads a highly productive research team of 15 staff and students. Dr Cheung has successfully conducted more than 30 projects in combination therapy, MYCN biology and prevention for embryonal cancer with greater than AUS$4.5 million of sourced funding. She also has outstanding research supervision skills, having supervised more than 40 postgraduate and undergraduate students in total with a 100% completion rate. Dr Cheung has extensive experience in neuroblastoma biology and drug development which has been demonstrated in her publications in high quality journals, including Nature Communications, 2021, 2019a & 2019b; Cancer Research, 2019 & 2018 and Science Translational Medicine 2019 & 2015. Dr Cheung directs and drives the research in all three themes in the Embryonal Cancer Therapy and Prevention Program: identification of oncogenic proteins in MYC-driven cancers; developing inhibitors for MYC oncoproteins; and developing childhood cancer prevention strategies.
Dr Belamy Cheung
Children's Cancer Institute Australia.
61 02 7209 6762
Project Grant, Cancer Council NSW, Application titled: “A novel combination therapy for childhood cancer” 2021-2023, $424,796.
Project Grant, the Trustees of the Anthony Rothe Memorial Trust, Application titled “Targeting PA2G4 as a novel treatment strategy for leukaemia and lymphoma". $115,000 per annum, 2020–2021.
Project Grant, Kids Cancer Alliance NSW, Application title “Prevention of Child Cancer – Down Syndrome”. Total of $160,000. 2018-2019.
NHMRC Project Grant , Application title “Therapeutic targeting of MYCN oncoprotein stability in neuroblastoma”. $590,206.20. 2017-2019.
UNSW Goldstar Award 2016, Proposal Title: Therapeutic targeting of the MYCN oncogenic signal in childhood neuroblastoma by inhibition of transcriptional elongation complex, FACT”. $40,000
Project Grant, CCIA Drug Screening Fund, titled “Identification of novel compounds which enhance the retinoid anti-cancer signal using a high-content TRIM16 translocation assay”. 2012, $10,000
Project Grant, Faculty of Medicine, University of NSW, project title: “Overcoming histone deacetylase inhibitor and retinoid drug resistance through novel combination therapies”, 2011, $11,000
Early Career Development fellowship, Cancer Institute NSW, 2007-2009, $570, 000
Project grant, Cure Cancer Australia, 2007, $75, 000
Current Research Projects:
1. Developing inhibitors for MYC oncoproteins.
2. Identification of co-factors for MYCN oncoprotein.
3. Establishing novel combination therapies of epigenetic drugs for cancer treatment.
4. Developing childhood cancer prevention strategies.